Program
onfekafusp alfa
Also written as “L19TNF”, “Onfekafusp alfa” and “L19TNF and TMZ”.
Its studies are mostly in Glioblastoma · Melanoma · Sarcoma · Carcinoma, Basal Cell · Glioma, led by Philogen.
Drug pageOnfekafusp alfa: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Philogen | 1512 open or running | phase 3since Oct 11, 2016 | Feb 24, 2014 | Jul 2028phase 2 · NCT06284590 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 24, 2014.
- Oct 11, 2016Phase 3 study in MelanomaNCT02938299 · 214 enrolled · France, Germany, Italy and more
- Dec 9, 2017Named onfekafusp alfaINNProposed as its International Nonproprietary Name in WHO's List 118
- Jan 12, 2018Phase 2 study in LeiomyosarcomaNCT03420014 · 114 planned · United States
- Dec 14, 2018Phase 2 study in Glioma of BrainNCT03779230 · 20 enrolled · Switzerland
- Jun 28, 2019Phase 1 study in SarcomaNCT04032964 · 2 enrolled · United States
- Apr 17, 2020Phase 2 study in Carcinoma, Basal CellNCT04362722 · 40 planned · Germany, Poland, Switzerland
- Jun 17, 2020Phase 2 study in GlioblastomaNCT04443010 · 226 planned · Switzerland
- Sep 25, 2020Phase 2 study in GlioblastomaNCT04573192 · 142 planned · France, Germany, Italy and more
- Nov 25, 2020Phase 3 study in SarcomaNCT04650984 · 102 planned · France, Germany, Italy and more
- Jan 22, 2021Phase 2 study in SarcomaNCT04733183 · 98 enrolled · France, Germany, Italy and more
- Feb 24, 2022Phase 1 study in GlioblastomaNCT05304663
- Jan 26, 2024Phase 2 study in MelanomaNCT06284590 · 162 planned · United States, Germany, Italy
- Mar 4, 2024Phase 2 study in GlioblastomaNCT06336291 · 90 enrolled · United States
- Jul 30, 2025Phase 2 study in GliomaNCT07120984 · 52 planned
- Nov 7, 2025Phase 2 study in Carcinoma, Basal CellNCT07227350 · 180 planned · United States, Germany, Greece and more
Ahead
- Jul 2028Primary completion: phase 2 study in MelanomaNCT06284590
- Jan 30, 2029Primary completion: phase 2 study in GliomaNCT07120984
- Feb 2031Primary completion: phase 2 study in Carcinoma, Basal CellNCT07227350
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07227350Carcinoma, Basal Cell · United States, Germany, Greece and more | 2 | Recruiting | Feb 2031 | 180 |
| NCT07120984Glioma | 2 | Not yet recruiting | Jan 30, 2029 | 52 |
| NCT06336291Glioblastoma · United States | 2 | Active, not recruiting | Jun 2026 | 90 |
| NCT06284590Melanoma · United States, Germany, Italy | 2 | Recruiting | Jul 2028 | 162 |
| NCT05304663Glioblastoma | 1 | Withdrawn | Dec 31, 2024 | 0 |
| NCT04733183Sarcoma · France, Germany, Italy and more | 2 | Active, not recruiting | Dec 2025 | 98 |
| NCT04650984Sarcoma · France, Germany, Italy and more | 3 | Recruiting | Dec 31, 2025 | 102 |
| NCT04573192Glioblastoma · France, Germany, Italy and more | 2 | Recruiting | Mar 2025 | 142 |
| NCT04443010Glioblastoma · Switzerland | 2 | Recruiting | Oct 2026 | 226 |
| NCT04362722Carcinoma, Basal Cell · Germany, Poland, Switzerland | 2 | Recruiting | Sep 2024 | 40 |
| NCT04032964Sarcoma · United States | 1 | Active, not recruiting | Dec 2024 | 2 |
| NCT03779230Glioma of Brain · Switzerland | 2 | Completed | Jun 27, 2023 | 20 |
| NCT03420014Leiomyosarcoma · United States | 2 | Recruiting | Dec 2024 | 114 |
| NCT02938299Melanoma · France, Germany, Italy and more | 3 | Active, not recruiting | Oct 2024 | 214 |
| NCT02076633Melanoma · Italy | 2 | Completed | May 2015 | 21 |
How it is read
Names in the registry
- “L19TNF”, 9 entries
- “Onfekafusp alfa”, 3 entries
- “L19TNF and TMZ”, 1 entry
- “L19TNF and CCNU”, 1 entry
- “L19TNF monotherapy”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 4 studies
- Melanoma, 3 studies
- Sarcoma, 3 studies
- Carcinoma, Basal Cell, 2 studies
- Glioma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.